Why Immunocore Holdings (IMCR) Is Back On Investor Radar
Immunocore Holdings (IMCR) has drawn fresh attention after reporting first quarter 2026 results, with revenue of US$106.68 million and net income of US$12.97 million compared with US$93.88 million and US$5.02 million a year earlier.
See our latest analysis for Immunocore Holdings.
Despite the stronger first quarter figures and a recent shelf registration for up to 2,497,743 ordinary shares, Immunocore Holdings’ share price has slipped, with the 30 day share price return down 9.25% and the 1 year total shareholder return down 1.03%. This points to fading momentum after earlier weakness.
If this kind of mixed reaction interests you, it can be helpful to see how other healthcare companies using AI are being priced and perceived through a curated list of 34 healthcare AI stocks
So with the share price down over the past year while value metrics and analyst targets imply a steep discount, you have to ask: is Immunocore trading below its worth, or is the market already factoring in its future growth?
Most Popular Narrative: 56.8% Undervalued
Immunocore’s most followed valuation narrative pegs fair value at about $66.57 per share, more than double the recent close at $28.76. This difference raises questions about what is included in those assumptions.
Momentum in pipeline diversification progressing late-stage trials in cutaneous melanoma (TEBE-AM, PRISM-MEL) and expanding into infectious and autoimmune diseases reduces single-product risk and sets the stage for multiple future revenue streams and earnings expansion.
Read the complete narrative. Read the complete narrative.
The valuation gap is linked to expectations about revenue trends, a potential shift from losses to profits, and an earnings multiple that would place Immunocore in line with higher rated biotech peers.
Result: Fair Value of $66.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh the risk that KIMMTRAK remains the main revenue driver while R&D spending and potential trial or regulatory setbacks put pressure on margins.
Find out about the key risks to this Immunocore Holdings narrative.
Next Steps
With sentiment looking mixed so far, it helps to look past the headlines and examine what the numbers actually show for yourself. To see what investors are currently optimistic about, review the 3 key rewards
Looking for more investment ideas?
If you stop with just one stock, you risk missing out on other opportunities that might fit your goals even better, so keep your watchlist working hard for you.
- Spot potential turnaround stories early by scanning 27 elite penny stocks with strong financials that already show stronger fundamentals than the typical low priced stock.
- Target quality at a discount by focusing on 47 high quality undervalued stocks that pair solid cash flows with balance sheets that support their current pricing.
- Prioritise resilience by reviewing 67 resilient stocks with low risk scores that score well on stability, so your portfolio is not relying on just a few volatile holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com